MHC type II immunogenic neoantigens have been screened using the following methods: (1) whole-exome sequencing (WES) or RNA-seq in tumour tissues to identify nonsynonymous somatic mutations; (2) synthesis of trimethylguanosine and antigenic polypeptides containing nonsynonymous mutations to activate autologous APCs; and (3) coculturing autologous CD4+ T cells with APCs, after which neoantigen and neoantigen-specific T cells are identified by monitoring the negative transcriptional regulation of cytokines such as IFN-γ, CD137, OX-40 and PD-1 (Figure 3). The gene discussed is CD4; the disease is neoplasm.